Gilead Reports Increased Cell Therapy Revenue; Yescarta and Tecartus Approved in the EU; New Galapagos Asset Added to Gilead’s Pipeline; Viral Vector Manufacturing Plant Receives FDA Approval; Gilead’s Q3 2022 Earnings Call Summary
On Thursday, October 27, Gilead (Kite) held their Q3 2022 earnings call (press release / presentation) highlighting an increase in revenue for their cell therapy franchise, while discussing recent EC approvals for Yescarta and Tecartus (CD19 CAR-Ts). Moreover, Gilead included a new cell therapy asset in its pipeline and confirmed the FDA approval of its new vector manufacturing facility in Oceanside, CA. Below, Celltelligence provides insights on Gilead’s cell therapy revenue increase, while discussing how recently gained approvals in several geographies could increase the ex-US sales for Yescarta and Tecartus.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.